Psyence Biomedical

Historical price data

Psyence Biomedical's mission is to develop and commercialize natural psilocybin-based therapies for psychological trauma, with a primary focus on adjustment disorder due to incurable cancer. Its key achievement is the advancement of its lead candidate into a Phase IIb clinical trial under a Health Canada-authorized Clinical Trial Application, supported by a proprietary GMP cultivation and production facility. The company's strategy hinges on the clinical validation of its natural psilocybin, vertical integration for supply chain control, and targeting a high-unmet-need indication to establish a specialized therapeutic niche.

Vertically integrated platform for the cultivation, extraction, and standardization of natural psilocybin from *Psilocybe cubensis* mushrooms, aiming to produce a pharmaceutical-grade API with a consistent alkaloid profile for use in medically supervised therapy.

Competes against well-funded synthetic psilocybin developers (e.g., COMPASS Pathways) and other natural extract companies (e.g., Filament Health). Psyence's niche focus on cancer-related adjustment disorder and vertical integration are its key strategic differentiators.